补肾活血方通过调控内皮祖细胞SIRT1/CXCL12/CXCR4/CXCR7轴对大鼠椎间盘退变及终板微循环的保护作用

Protective effects of Bushen Huoxue Formula on intervertebral disc degeneration and endplate microcirculation in rats via the SIRT1/CXCL12/CXCR4/CXCR7 axis in endothelial progenitor cells

  • 摘要:
    目的 探讨补肾活血方(BSHXF)对椎间盘退变(IVDD)、软骨终板微血管重塑及内皮祖细胞(EPCs)功能的影响,以及沉默信息调节因子1(SIRT1)/C-X-C基序趋化因子配体12(CXCL12)/C-X-C基序趋化因子受体4(CXCR4)/C-X-C基序趋化因子受体7(CXCR7)信号通路在其中的潜在作用。
    方法 本研究包括体内与体外实验。在体内实验中,将24只4 − 6周龄雄性SD大鼠分为4组:大鼠对照组、大鼠模型组、大鼠BSHXF组及大鼠EX527 + BSHXF组,每组6只。通过对大鼠尾部椎间盘施加约11 N的持续轴向压缩2周以构建IVDD模型。模型建立后,大鼠BSHXF组每日灌胃给予BSHXF17.71 g/(kg·d);大鼠EX527 + BSHXF组在接受相同BSHXF给药方案的同时,每日腹腔注射5 mg/kg的SIRT1抑制剂EX527,连续干预2周。采用磁共振成像(MRI)、Pfirrmann分级及苏木精-伊红(HE)染色评估椎间盘退变程度;通过CD31免疫组化染色评估终板微血管密度;利用实时荧光定量逆转录聚合酶链式反应(RT-qPCR)检测椎间盘及终板组织中SIRT1、CXCL12、CXCR4和CXCR7的mRNA表达水平,采用蛋白质印迹法和免疫荧光染色检测其蛋白表达。在体外实验中,从另外6只SD大鼠中分离培养大鼠骨髓源性EPCs,并通过CD34/CD133免疫荧光染色进行鉴定。将EPCs分为对照组、BSHXF组、siRNA-SIRT1组、siRNA + BSHXF组及塞来昔布组。BSHXF相关组采用由另外6只SD大鼠制备的10% BSHXF含药血清进行干预,并通过靶向SIRT1的小干扰RNA(si-SIRT1)技术敲低SIRT1的表达。随后,分别采用细胞计数试剂盒-8(CCK-8)、Transwell迁移实验和Matrigel成管实验评估EPCs的细胞活力、迁移能力及血管形成能力。同时,通过RT-qPCR和蛋白质印迹法检测EPCs中SIRT1、CXCL12、CXCR4和CXCR7的mRNA和蛋白表达水平。
    结果 体内实验显示,轴向压缩导致明显的椎间盘退变,表现为T2加权信号强度降低、椎间隙高度下降及Pfirrmann分级达到IV – V级。与大鼠模型组及大鼠EX527 + BSHXF组相比,大鼠BSHXF组的组织学退变明显减轻,且终板微血管密度显著增加(P < 0.05)。此外,与大鼠模型组及大鼠EX527联合BSHXF组相比,BSHXF显著上调了椎间盘及终板组织中SIRT1、CXCL12、CXCR4和CXCR7的mRNA与蛋白表达水平(P < 0.05);免疫荧光分析进一步证实了大鼠BSHXF组中上述标志物的高表达(P < 0.05)。体外实验表明,与对照组、si-SIRT1组及si-SIRTI + BSHXF组相比,BSHXF含药血清显著提高了EPCs的细胞活力、迁移能力,并增加了总成管长度和分支点数量(P < 0.05)。BSHXF组与塞来昔布组的成管能力无显著性差异(P > 0.05)。相反,敲低SIRT1则显著削弱了EPCs的血管生成相关功能,并逆转了BSHXF对EPCs活力、迁移和成管能力的促进作用,si-SIRT1组与si-SIRT1 + BSHXF组之间无显著差异(P > 0.05)。
    结论 BSHXF可减轻大鼠尾部椎间盘压缩模型中的IVDD相关退行性改变,增加终板微血管密度,同时在体外增强EPCs的增殖、迁移及成管能力。BSHXF对IVDD终板微循环的改善作用可能与EPCs中SIRT1介导的CXCL12/CXCR4/CXCR7信号轴调控有关。

     

    Abstract:
    Objective To investigate the efficacy of the Bushen Huoxue Formula (补肾活血方, BSHXF) in alleviating intervertebral disc degeneration (IVDD), improving endplate microcirculation, and enhancing endothelial progenitor cell (EPC) function, while investigating the potential role of the sirtuin 1 (SIRT1)/C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine receptor 7 (CXCR7) signaling pathway.
    Methods This study comprised both in vivo and in vitro experiments. In vivo, 24 male Sprague-Dawley (SD) rats (4 - 6 weeks old) were used, and allocated into four groups (n = 6 per group): Rat-Control, Rat-Model, Rat-BSHXF, and Rat-EX527 + BSHXF groups. IVDD was induced by applying continuous axial compression (approximately 11 N) to the caudal intervertebral discs for two weeks. Following model establishment, rats in the Rat-BSHXF group received oral BSHXF at 17.71 g/(kg·d) once daily, whereas those in the Rat-EX527 + BSHXF group received the SIRT1 inhibitor EX527 at 5 mg/kg by intraperitoneal injection once daily in addition to the same BSHXF regimen for two consecutive weeks. Disc degeneration was evaluated using magnetic resonance imaging (MRI), Pfirrmann grading, and hematoxylin and eosin (HE) staining. Endplate microvascular density was assessed via CD31 immunostaining. The mRNA expression levels of SIRT1, CXCL12, CXCR4, and CXCR7 in disc and endplate tissues were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR), whereas their protein expression levels were assessed using Western blot and immunofluorescence staining. In vitro, rat bone marrow-derived EPCs were isolated from a separate cohort of six SD rats, cultured, and identified via CD34/CD133 immunofluorescence staining. The EPCs were allocated into Control, BSHXF, si-SIRT1, si-SIRT1 + BSHXF, and Celecoxib groups. Cells in the BSHXF-related groups were treated with 10% BSHXF-containing serum prepared using another separate cohort of six SD rats, and SIRT1 knockdown was achieved using SIRT1 targeting small interfering RNA (si-SIRT1). EPC viability, migration, and tube formation were evaluated using cell counting kit-8 (CCK-8), transwell migration, and Matrigel tube formation assays, respectively. Additionally, the mRNA and protein expression levels of SIRT1, CXCL12, CXCR4, and CXCR7 in EPCs were measured via RT-qPCR and Western blot, respectively.
    Results In vivo, axial compression induced significant disc degeneration, characterized by reduced T2 signal intensity, decreased disc height, and Pfirrmann grade IV – V changes. Compared with the Rat-Model and Rat-EX527 + BSHXF groups, the Rat-BSHXF group exhibited less severe histological degeneration and significantly increased endplate microvascular density (P < 0.05). Furthermore, BSHXF significantly upregulated the mRNA and protein expression levels of SIRT1, CXCL12, CXCR4, and CXCR7 in disc and endplate tissues compared with both the Rat-Model and Rat-EX527 + BSHXF groups (P < 0.05). These elevated expression levels in the Rat-BSHXF group were further corroborated by immunofluorescence analysis (P < 0.05). In vitro, treatment with BSHXF-containing serum significantly enhanced EPC viability, migration, total tube length, and branch point formation compared with the Control, si-SIRT1, and si-SIRT1 + BSHXF groups (P < 0.05). No significant differences in tube formation were observed between the BSHXF and Celecoxib groups (P > 0.05). Conversely, SIRT1 knockdown markedly impaired EPCs angiogenesis-related functions and abrogated the BSHXF-induced enhancements in EPCs viability, migration, and tube formation, with no significant differences observed between the si-SIRT1 and si-SIRT1 + BSHXF groups (P > 0.05).
    Conclusion BSHXF attenuated IVDD-related degenerative changes and increased endplate microvascular density in a rat model of caudal disc compression, while enhancing EPC viability, migration, and angiogenesis in vitro. These findings suggest that the effects of BSHXF on endplate microcirculation during IVDD may be associated with the SIRT1-related modulation of the CXCL12/CXCR4/CXCR7 axis in EPCs.

     

/

返回文章
返回